Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Oxygen Strategy

The Vector Issue 3 banner

Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will...

Genesis Research Group

promo for Tim's discussion of GLOBE Final Rule

On GLOBE Final Rule

The publication of the GLOBE Final Rule provides important clarity on the administration's approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally....

Genesis Research Group

- PMLiVE

Chiesi UK and Ireland supports NHS workforce to address COPD diagnosis backlog

An estimated two million people in the UK are living with undiagnosed chronic obstructive pulmonary disease

- PMLiVE

Changing the narrative: why hidden struggles matter

On Suicide Prevention Day, we’re focusing on something often overlooked: the difference between what’s visible and what’s actually being carried. Many people living with long-term or chronic illness experience challenges...

Mednet

- PMLiVE

Cutting the friction from health comms through whole-person design

Good design can’t change the reality of illness, remove the pain, or stop the uncertainty. But it can stop learning what comes next from being another burden to carry.

Mednet

- PMLiVE

NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis

Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life

Sarah Alwardt of Genesis Research Group

Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...

Genesis Research Group

- PMLiVE

Number of women in England receiving HRT on the NHS more than doubles

A record two million women were prescribed hormone replacement therapy in 2025/26 compared to 0.8 million in 2020/21

- PMLiVE

Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

Impetus Digital

Genesis Research Group free access image

Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...

Genesis Research Group

- PMLiVE

Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands

Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing...

Uniphar

Two_Women_Running_Making_Health_Whole

The silent drop-off: How disengagement shows up in everyday behaviour

In healthcare, disengagement rarely announces itself. It doesn’t always appear as refusal or a clear decision to stop treatment. More often, it shows up quietly, in what is delayed, avoided...

Mednet

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links